10-Q: Medtronic Reports Q3 2025 Results: Revenue and Earnings Show Growth

Medtronic's Q3 2025 results reveal growth in net sales and earnings per share, driven by strong performance in key segments.

Summary

• Medtronic's net sales for Q3 2025 were $8.292 billion, up from $8.089 billion in Q3 2024.
• Diluted earnings per share were $1.01 for both Q3 2025 and Q3 2024.
• Net income attributable to Medtronic was $1.294 billion in Q3 2025, compared to $1.322 billion in Q3 2024.
• For the nine months ended January 24, 2025, net sales were $24.610 billion, up from $23.775 billion in the same period last year.
• Diluted earnings per share for the nine-month period were $2.79, compared to $2.27 in the prior year.
• Net income attributable to Medtronic for the nine-month period was $3.606 billion, up from $3.022 billion.
• Operating cash flow for the nine months ended January 24, 2025, was $4.516 billion.
• The company is facing legal challenges, including intellectual property and product liability matters.
• Medtronic is implementing a global minimum tax in fiscal year 2025.
• A new Executive Vice President & Chief Financial Officer, Thierry Pieton, has been appointed.
• The company is involved in various legal proceedings, including intellectual property, product liability, antitrust, and environmental matters.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive growth in revenue and earnings, but also acknowledges risks and challenges. The sentiment is moderately positive.

Positives

• Net sales increased by 3% in Q3 2025 compared to Q3 2024.
• Net sales for the nine months ended January 24, 2025 increased by 4% compared to the same period last year.
• The Cardiovascular, Neuroscience, and Diabetes segments all experienced growth in net sales.
• The company is in compliance with covenants under the Credit Facility and Senior Notes.
• Medtronic is committed to strengthening its anti-corruption compliance programs and practices.

Negatives

• Net income attributable to Medtronic decreased slightly in Q3 2025 compared to Q3 2024.
• The Medical Surgical segment experienced a decrease in net sales for both the three and nine months ended January 24, 2025.
• The company is involved in various legal proceedings, which could have a material adverse impact.
• The company increased its liability pertaining primarily to certain prior years since 2015 by $90 million during the three months ended July 26, 2024, as a reduction to net sales in the consolidated statements of income due to Italian payback legislation.
• The company is facing challenges related to tender pricing in China.

Risks

• The company faces competition in the medical device industry.
• Delays in regulatory approvals could impact product launches.
• Public health crises and geopolitical conflicts could negatively impact the business.
• Reductions or interruptions in the supply chain could affect operations.
• Failure to complete or achieve the intended benefits of acquisitions or divestitures could impact financial performance.
• Adverse regulatory actions could result in fines, penalties, and other remedies.
• Litigation results could have a material adverse impact on the company's financial condition.
• Healthcare policy changes could affect reimbursement and pricing.
• Cybersecurity and privacy incidents could disrupt operations and compromise data.
• Fluctuations in currency exchange rates could impact earnings and cash flows.
• Inflation could increase costs and expenses.
• The company is subject to ongoing governmental proceedings and investigations.

Future Outlook

The company anticipates that macro-economic and geopolitical factors could negatively impact the business, including competitive product launches, pricing pressure, changes in global trade policies, fluctuations in currency exchange rates, general price inflation, changes in interest rates, reimbursement challenges, impacts from changes in the mix of product offerings, delays in product registration approvals, replacement cycle challenges, and supply chain challenges.

Industry Context

Medtronic operates in the highly competitive medical device industry, facing challenges from both established players and emerging companies. The company's performance is influenced by factors such as technological innovation, regulatory approvals, reimbursement policies, and healthcare spending trends. Medtronic's focus on strategic acquisitions and product development is aimed at maintaining its market leadership and expanding its presence in key therapeutic areas.

Comparison to Industry Standards

• Medtronic's financial performance can be compared to other large medical device companies such as Johnson & Johnson, Abbott Laboratories, and Stryker.
• These companies also operate globally and face similar challenges related to regulatory approvals, reimbursement, and competition.
• Medtronic's growth rates in certain segments, such as Cardiovascular and Neuroscience, can be benchmarked against the industry average to assess its relative performance.
• The company's R&D spending as a percentage of revenue can be compared to industry peers to evaluate its commitment to innovation.
• Medtronic's profitability metrics, such as gross margin and operating margin, can be compared to industry benchmarks to assess its operational efficiency.

Management Changes

Legal Proceedings

• The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California.
• Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries.
• Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021.
• The Company is a defendant in civil antitrust litigation brought by Applied Medical Resources Corporation in the U.S. District Court for the Central District of California, alleging that the Company has engaged in anticompetitive and monopolistic conduct relating to its sales of advanced bipolar devices, including under contracts with group purchasing organizations.
• The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine.
• The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination.
• Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in China regarding certain activities in certain foreign countries, including China.
• In July 2024, two rulings by the Constitutional Court of Italy found that the medical device payback law is constitutional.
• In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006.
• The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRSs position, but also made certain modifications to the Medtronic, Inc. tax returns as filed.
• In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion.
• The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings.
• The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023.
• Medtronic, Inc.s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.

Stakeholder Impact

• Shareholders: The company is focused on returning value through dividends and share repurchases.
• Employees: The company is implementing restructuring initiatives that may impact employment.
• Customers: The company is focused on delivering innovative products and therapies to improve patient outcomes.
• Suppliers: The company is managing its supply chain to ensure a reliable supply of products.
• Creditors: The company is in compliance with debt covenants and maintains a strong balance sheet.

Next Steps

• The company will continue to monitor the impacts of legislation, regulatory guidance, and regulations issued in the countries in which it does business.
• The company will continue to evaluate and strengthen its anti-corruption compliance programs and practices.
• The company will continue to focus on returning value to shareholders through dividends and share repurchases.
• The company will continue to develop, obtain regulatory approval of and commercialize the products within its pipeline.

Key Dates